查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1587395

美國生物製藥第三方物流市場規模、佔有率、趨勢分析報告：依供應鏈、服務、產品、細分市場預測，2025-2030年

U.S. Biopharmaceutical Third-party Logistics Market Size, Share & Trends Analysis Report By Supply Chain, By Service, By Product, And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 120 Pages | 商品交期: 2-10個工作天內

價格

美國生物製藥第三方物流市場成長及趨勢：

Grand View Research, Inc.最新報告顯示，預計到2030年，美國生物製藥第三方物流市場規模將達到874.4億美元，2025年至2030年複合年成長率為7.56%，預計將達到這一水平。

對新型生技藥品的需求不斷成長以及管理它們的需求正在推動市場成長。對跨不同地區運輸生技藥品的溫控物流服務的需求不斷增加，以及生物製藥公司擴大分銷網路以提高銷售，也推動了成長。

由於航空貨運能力下降以及倉庫和機場勞動力減少，COVID-19大流行在一定程度上對全球物流產生了重大影響。地方政府的決定，例如關閉物流基礎設施、實施行動限制以及提出額外要求以抑制病毒傳播，也正在影響物流服務。這對許多供應業務造成了嚴重干擾。

在美國，政府對運輸和就地避難的監管正在逐步放鬆，生物製藥第三方物流行業的未來看起來一片光明。疫情期間，低溫運輸物流需求激增。預計 2021 年 COVID-19 疫苗的生產和分銷將出現成長。例如，2021 年 3 月，聯邦快遞開始將 McKesson Corp. 的 COVID-19 疫苗運送到美國各地的中心。自 2020 年 12 月中旬以來，該公司已出貨數百萬支 COVID-19 疫苗。

美國生物製藥第三方物流市場亮點

  • 低溫運輸物流板塊銷售佔比最大，2024年為58.39%。該細分市場主要是由不需要嚴格溫度控制的標準生物藥品的分銷推動的，從而允許擴大運輸和儲存選擇。
  • 2024年，倉儲業將主導市場。該部門整合了自動化倉儲和即時庫存管理等高科技系統，為溫度敏感和非溫度敏感產品提供專門的儲存解決方案。
  • 預計到 2024 年，特種藥品領域將佔據市場最大的收益佔有率，並在估計期間呈現最高的複合年成長率。這是由於這些高價值且通常對溫度敏感的藥品具有獨特的處理要求。

目錄

第1章調查方法和範圍

第 2 章執行摘要

第3章美國生物製藥第三方物流（3PL）市場變數、趨勢與範圍

  • 市場體系展望
    • 母市場展望
    • 配套市場前景
  • 市場動態
    • 市場促進因素分析
    • 市場限制因素分析
  • 技術景觀
  • 定價模式分析
  • 產業生態系統分析
  • 市場分析工具
    • 波特五力分析
    • PESTEL分析
    • COVID-19 影響分析

第4章美國生物製藥第三方物流市場：供應鏈估算及趨勢分析

  • 細分儀表板
  • 生醫第三方物流市場：供應鏈波動分析
  • 2018-2030年美國生物製藥第三方物流（3PL）市場估計與預測
  • 低溫運輸
  • 非低溫運輸

第5章美國生物製藥第三方物流市場：服務評估與趨勢分析

  • 細分儀表板
  • 生物製藥第三方物流市場：服務變化分析
  • 2018-2030年美國生物製藥第三方物流（3PL）市場估計與預測
  • 運輸
    • 空運
    • 海運
    • 陸運
  • 倉儲
  • 其他

第6章美國生物製藥第三方物流市場：產品估算與趨勢分析

  • 細分儀表板
  • 生物製藥第三方物流市場：產品變異分析
  • 2018-2030年美國生物製藥第三方物流（3PL）市場估計與預測
  • 特種藥品
  • 非專利的
  • 血漿衍生產品
  • 其他

第7章 競爭格局

  • 公司分類
    • 市場領導者
    • 新興企業
  • 公司市場分析
  • 公司簡介
    • UPS Healthcare
    • Cardinal Health
    • KUEHNE+NAGEL
    • AmerisourceBergen Corp.
    • McKesson Corporation
    • Thermo Fisher Scientific
    • DHL International GmbH
    • DB Schenker
    • Kerry Logistics Network Ltd.
    • CEVA Logistics
    • Agility Logistics
    • SF Express
    • XPO Logistics
    • Cencora, Inc.
    • EVERSANA
Product Code: GVR-4-68038-381-2

U.S. Biopharmaceutical Third-party Logistics Market Growth & Trends:

The U.S. biopharmaceutical third-party logistics market size is estimated to reach USD 87.44 billion by 2030, registering to grow at a CAGR of 7.56% from 2025 to 2030 according to a new report by Grand View Research, Inc. Increasing demand for novel biologics and the need to manage those is boosting the market growth. Besides, rising demand for temperature-controlled logistic services to transport biologics in various regions and growing distribution networks of biopharmaceutical companies to improve their sales are factors driving the growth.

The COVID-19 pandemic has had a major impact on global logistics to some extent due to diminished air freight capacity and reduced workforce at warehouses and airports. The decisions of local authorities to shut down the logistic infrastructure, enforce movement restrictions, or put in place additional requirements to suppress transmission of the virus have also impacted the logistic services. This has significantly hindered many supply operations.

The future seems lucrative for the biopharmaceutical third-party logistics industry in the U.S. with the retraction of government regulations related to transportation and shelter-in-place mandates. A sudden surge in the demand for cold chain logistics was observed during the pandemic. Growth in the manufacture and distribution of the COVID-19 vaccine is expected throughout 2021. For instance, in March 2021, FedEx Express started shipping COVID-19 vaccines for McKesson Corp. to centers all across the U.S. The company has already shipped millions of COVID-19 vaccines since mid-December 2020.

U.S. Biopharmaceutical Third-party Logistics Market Highlights

  • The non-cold chain logistics segment accounted for the largest revenue share of 58.39% in 2024. The segment is primarily driven by the distribution of standard biopharmaceutical products that do not require stringent temperature control, allowing for a broader range of transportation and storage options.
  • The warehousing and storage segment dominated the market in 2024. This segment provides specialized storage solutions for both temperature-sensitive and non-sensitive products, integrating high-tech systems such as automated warehouses and real-time inventory management.
  • The specialty drugs segment accounted for the largest revenue share in the market in 2024 and is expected to witness the highest CAGR over the estimated timeline. This is attributed to the unique handling requirements of these high-value, often temperature-sensitive medications.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
    • 1.1.1. Estimates and forecast timeline
  • 1.2. Market Definitions
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
      • 1.7.1.1. Approach 1: Commodity flow approach
    • 1.7.2. Volume price analysis (Model 2)
      • 1.7.2.1. Approach 2: Volume price analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Abbreviations
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. U.S. Biopharmaceutical Third-Party Logistics (3PL) Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Ancillary Market Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
    • 3.2.2. Market Restraint Analysis
  • 3.3. Technology Landscape
  • 3.4. Pricing Model Analysis
  • 3.5. Industry Ecosystem Analysis
  • 3.6. Market Analysis Tools
    • 3.6.1. Porter's Five Forces Analysis
    • 3.6.2. PESTEL Analysis
    • 3.6.3. COVID-19 Impact Analysis

Chapter 4. U.S. Biopharmaceutical Third-Party Logistics Market: Supply Chain Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Biopharmaceutical Third-Party Logistics Market: Supply Chain Movement Analysis
  • 4.3. U.S. Biopharmaceutical Third-Party Logistics (3PL) Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 4.4. Cold Chain
    • 4.4.1. Cold Chain Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 4.5. Non-Cold Chain
    • 4.5.1. Non-Cold Chain Market Estimates and Forecasts, 2018 - 2030 (USD Billion)

Chapter 5. U.S. Biopharmaceutical Third-Party Logistics Market: Service Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. Biopharmaceutical Third-party Logistics Market: Service Movement Analysis
  • 5.3. U.S. Biopharmaceutical Third-Party Logistics (3PL) Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 5.4. Transportation
    • 5.4.1. Transportation Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 5.4.2. Air Freight
      • 5.4.2.1. Air Freight Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 5.4.3. Sea Freight
      • 5.4.3.1. Sea Freight Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 5.4.4. Overland Transportation
      • 5.4.4.1. Overland Transportation Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 5.5. Warehousing & Storage
    • 5.5.1. Warehousing & Storage Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 5.6. Others
    • 5.6.1. Others Market Estimates and Forecasts, 2018 - 2030 (USD Billion)

Chapter 6. U.S. Biopharmaceutical Third-Party Logistics Market: Product Estimates & Trend Analysis

  • 6.1. Segment Dashboard
  • 6.2. Biopharmaceutical Third-Party Logistics Market: Product Movement Analysis
  • 6.3. U.S. Biopharmaceutical Third-Party Logistics (3PL) Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 6.4. Specialty Drugs
    • 6.4.1. Specialty Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 6.5. Generics
    • 6.5.1. Generics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 6.6. Plasma Derived Products
    • 6.6.1. Plasma Derived Products Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 6.7. Others
    • 6.7.1. Others Market Estimates and Forecasts, 2018 - 2030 (USD Billion)

Chapter 7. Competitive Landscape

  • 7.1. Company Categorization
    • 7.1.1. Market Leaders
    • 7.1.2. Emerging Players
  • 7.2. Company Market Position Analysis
  • 7.3. Company Profiles
    • 7.3.1. UPS Healthcare
      • 7.3.1.1. Company Overview
      • 7.3.1.2. Financial Performance
      • 7.3.1.3. Service Benchmarking
      • 7.3.1.4. Strategic Initiatives
    • 7.3.2. Cardinal Health
      • 7.3.2.1. Company Overview
      • 7.3.2.2. Financial Performance
      • 7.3.2.3. Service Benchmarking
      • 7.3.2.4. Strategic Initiatives
    • 7.3.3. KUEHNE + NAGEL
      • 7.3.3.1. Company Overview
      • 7.3.3.2. Financial Performance
      • 7.3.3.3. Service Benchmarking
      • 7.3.3.4. Strategic Initiatives
    • 7.3.4. AmerisourceBergen Corp.
      • 7.3.4.1. Company Overview
      • 7.3.4.2. Financial Performance
      • 7.3.4.3. Service Benchmarking
      • 7.3.4.4. Strategic Initiatives
    • 7.3.5. McKesson Corporation
      • 7.3.5.1. Company Overview
      • 7.3.5.2. Financial Performance
      • 7.3.5.3. Service Benchmarking
      • 7.3.5.4. Strategic Initiatives
    • 7.3.6. Thermo Fisher Scientific
      • 7.3.6.1. Company Overview
      • 7.3.6.2. Financial Performance
      • 7.3.6.3. Service Benchmarking
      • 7.3.6.4. Strategic Initiatives
    • 7.3.7. DHL International GmbH
      • 7.3.7.1. Company Overview
      • 7.3.7.2. Financial Performance
      • 7.3.7.3. Service Benchmarking
      • 7.3.7.4. Strategic Initiatives
    • 7.3.8. DB Schenker
      • 7.3.8.1. Company Overview
      • 7.3.8.2. Financial Performance
      • 7.3.8.3. Service Benchmarking
      • 7.3.8.4. Strategic Initiatives
    • 7.3.9. Kerry Logistics Network Ltd.
      • 7.3.9.1. Company Overview
      • 7.3.9.2. Financial Performance
      • 7.3.9.3. Service Benchmarking
      • 7.3.9.4. Strategic Initiatives
    • 7.3.10. CEVA Logistics
      • 7.3.10.1. Company Overview
      • 7.3.10.2. Financial Performance
      • 7.3.10.3. Service Benchmarking
      • 7.3.10.4. Strategic Initiatives
    • 7.3.11. Agility Logistics
      • 7.3.11.1. Company Overview
      • 7.3.11.2. Financial Performance
      • 7.3.11.3. Service Benchmarking
      • 7.3.11.4. Strategic Initiatives
    • 7.3.12. SF Express
      • 7.3.12.1. Company Overview
      • 7.3.12.2. Financial Performance
      • 7.3.12.3. Service Benchmarking
      • 7.3.12.4. Strategic Initiatives
    • 7.3.13. XPO Logistics
      • 7.3.13.1. Company Overview
      • 7.3.13.2. Financial Performance
      • 7.3.13.3. Service Benchmarking
      • 7.3.13.4. Strategic Initiatives
    • 7.3.14. Cencora, Inc.
      • 7.3.14.1. Company Overview
      • 7.3.14.2. Financial Performance
      • 7.3.14.3. Service Benchmarking
      • 7.3.14.4. Strategic Initiatives
    • 7.3.15. EVERSANA
      • 7.3.15.1. Company Overview
      • 7.3.15.2. Financial Performance
      • 7.3.15.3. Service Benchmarking
      • 7.3.15.4. Strategic Initiatives

List of Tables

  • Table 1. List of Secondary Sources
  • Table 2. List of Abbreviations
  • Table 3. U.S. Biopharmaceutical Third-Party Logistics (3PL) Market by Supply Chain, 2018 - 2030 (USD Billion)
  • Table 4. U.S. Biopharmaceutical Third-Party Logistics (3PL) Market by Service, 2018 - 2030 (USD Billion)
  • Table 5. U.S. Biopharmaceutical Third-Party Logistics (3PL) Market by Product, 2018 - 2030 (USD Billion)

List of Figures

  • Fig. 1 Information Procurement
  • Fig. 2 Primary Research Pattern
  • Fig. 3 Market Research Approaches
  • Fig. 4 Value Chain-Based Sizing & Forecasting
  • Fig. 5 Market Formulation & Validation
  • Fig. 6 Biopharmaceutical Third-Party Logistics, Market Segmentation
  • Fig. 7 Market Driver Analysis (Current & Future Impact)
  • Fig. 8 Market Restraint Analysis (Current & Future Impact)
  • Fig. 9 Porter's Five Forces Analysis
  • Fig. 10 PESTEL By SWOT Analysis
  • Fig. 11 U.S. Biopharmaceutical Third-Party Logistics, for Cold Chain Logistics, 2018 - 2030 (USD Million)
  • Fig. 12 U.S. Biopharmaceutical Third-Party Logistics, for Non-cold Chain Logistics, 2018 - 2030 (USD Million)
  • Fig. 13 U.S. Biopharmaceutical Third-Party Logistics, for Transportation, 2018 - 2030 (USD Million)
  • Fig. 14 U.S. Biopharmaceutical Third-Party Logistics, for Air Freight, 2018 - 2030 (USD Million)
  • Fig. 15 U.S. Biopharmaceutical Third-Party Logistics, for Sea Freight, 2018 - 2030 (USD Million)
  • Fig. 16 U.S. Biopharmaceutical Third-Party Logistics, for Overland, 2018 - 2030 (USD Million)
  • Fig. 17 U.S. Biopharmaceutical Third-Party Logistics, for Warehousing and Storage, 2018 - 2030 (USD Million)
  • Fig. 18 U.S. Biopharmaceutical Third-Party Logistics, for Other Services, 2018 - 2030 (USD Million)
  • Fig. 19 U.S. Biopharmaceutical Third-Party Logistics, for Specialty Drugs, 2018 - 2030 (USD Million)
  • Fig. 20 U.S. Biopharmaceutical Third-Party Logistics, for Generics, 2018 - 2030 (USD Million)
  • Fig. 21 U.S. Biopharmaceutical Third-Party Logistics, for Plasma Derived Products, 2018 - 2030 (USD Million)
  • Fig. 22 U.S. Biopharmaceutical Third-Party Logistics, for Others, 2018 - 2030 (USD Million)